People · Operator
Named in public records as an officer, director or promoter · active 2012–2018 · Biotech / Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akoya Biosciences, Inc. | — | Biotech / Pharma | Series B | $33.5M | $901.1M | 2017 |
| BINA Technologies Inc. | — | Other Technology | Series A | $6.6M | $117.9M | 2012 |
Garry Nolan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Garry Nolan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Babak Yazdani | 1 | 18 |
| Tim Guleri | 1 | 13 |
| Farzad Naimi | 1 | 5 |
| Rob Hart | 1 | 5 |
| Robert Shepler | 1 | 4 |
| Thomas Raffin | 1 | 4 |
| Matthew Winkler | 1 | 3 |
| Wing Hung Wong | 1 | 2 |
| Wing Wong | 1 | 2 |
| Harsh Patel | 1 | 2 |
| Garry P. Nolan | 1 | 2 |
| Richard Murdock | 1 | 2 |
| Narges Bani Asadi | 1 | 1 |
| Farzad Hung Naimi | 1 | 1 |
| Babak Hung Yazdani | 1 | 1 |
| Brian McKelligon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.